Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 4/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | PARP1 | P09874 | 1/20 | 0.45 |
| ▸ | SPR | P35270 | 1/20 | 0.44 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
| ▸ | TDO2 | P48775 | 1/20 | 0.42 |
| ▸ | REN | P00797 | 4/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL646157 | 0.83 | LMNA (0.61) | HRH4LMNASPR | |
| SCHEMBL937500 | 0.82 | LMNA (0.71) | HRH4SIGMAR1LMNARXFP1REN | |
| SCHEMBL20594360 | 0.81 | LMNA (0.65) | LMNASPR | |
| SCHEMBL2089753 | 0.79 | LMNA (0.47) | HRH4LMNASPR | |
| Hydrochloric Acid SCHEMBL2849329 | 0.77 | KDM4E (0.58) | HRH4SIGMAR1PARP1HSP90AA1RXFP1 | |
| SCHEMBL6141643 | 0.77 | HRH4 (0.78) | HRH4HRH3 | |
| SCHEMBL226167 | 0.75 | SIGMAR1 (0.56) | HRH4SIGMAR1HSP90AA1RXFP1TDO2 | |
| SCHEMBL3087941 | 0.75 | PARP1 (0.63) | HRH4SIGMAR1PARP1HSP90AA1RXFP1 | |
| SCHEMBL31220894 | 0.75 | PARP1 (0.63) | HRH4SIGMAR1PARP1HSP90AA1RXFP1 | |
| Hydrochloric Acid SCHEMBL224420 | 0.74 | SIGMAR1 (0.54) | HRH4SIGMAR1HSP90AA1RXFP1TDO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100075953-A1 | SUBSTITUTED PIPERAZINES, (1,4) DIAZEPINES, AND 2,5-DIAZABICYCLO (2.2.1) HEPTANES AS HISTAMINE H1 AND/OR H3 ANTAGONISTS OR HISTAMINE H3 REVERSE ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2010-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100075953-A1 | SUBSTITUTED PIPERAZINES, (1,4) DIAZEPINES, AND 2,5-DIAZABICYCLO (2.2.1) HEPTANES AS HISTAMINE H1 AND/OR H3 ANTAGONISTS OR HISTAMINE H3 REVERSE ANTAGONISTS | HRH3, HRH4, HRH2 | HRH4 2/4885SIGMAR1 487/4885LMNA 4344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.